Clinical trial
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects…
NCT00077779 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00077779 |
|---|---|
| Title | Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease |
| Official title | A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease |
| Acronym | CHARM |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Adalimumab |
| Enrollment | 854 |
| Start date | Jul 1, 2003 |
| First posted | Feb 16, 2004 |
| Last update posted | Sep 26, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: